Anthony Champiré, Rayan Berabez, Abdennour Braka, Aurélie Cosson, Justine Corret, Caroline Girardin, Amandine Serrano, Samia Aci-Sèche, Pascal Bonnet, Béatrice Josselin, Pierre Brindeau, Sandrine Ruchaud, Rémy Leguevel, Deep Chatterjee, Sebastian Mathea, Stefan Knapp, Régis Brion, Franck Verrecchia, Béatrice Vallée, Karen Plé, Hélène Bénédetti, Sylvain Routier
LIM Kinases, LIMK1 and LIMK2, have become promising targets for the development of inhibitors with potential application for the treatment of several major diseases. LIMKs play crucial roles in cytoskeleton remodeling as downstream effectors of small G proteins of the Rho-GTPase family, and as major regulators of cofilin, an actin depolymerizing factor. In this article we describe the conception, synthesis, and biological evaluation of novel tetrahydropyridine pyrrolopyrimidine LIMK inhibitors. Homology models were first constructed to better understand the binding mode of our preliminary compounds and to explain differences in biological activity...
April 9, 2024: European Journal of Medicinal Chemistry